摘要
目的评价立体定向放射治疗联合厄洛替尼治疗晚期非小细胞肺癌的疗效和不良反应。方法 42例晚期非小细胞肺癌患者均经病理组织学或细胞学检查确诊。所有病例于2008-08至2012-08均行伽马刀治疗后,开始口服靶向药物厄洛替尼,100～150 mg/d,进食1 h前或进食2 h后服药;连续不间断服药至少2个月。伽马刀治疗结束至少1个月后评价疗效及不良反应。结果全组42例患者客观有效率(response rate,RR)19.9%(8/42),疾病控制率(disease control rate,DCR)61.9%(26/42);中位疾病进展时间(the median time to disease progression,TTP)5.2个月,中位生存期(median survival time,MST)11.5个月。不良反应多为Ⅰ/Ⅱ度,Ⅲ/Ⅳ度较少。结论采用γ-立体定向放疗结合靶向药物厄洛替尼对晚期非小细胞肺-癌进行治疗效果较好,不良反应轻微,多数患者能耐受治疗。
Objective To evaluate the efficacy and adverse effects of γ- SBRT combinaed with targeted drug erlotinib on advanced stage non - small cell lung cancer. Methods Forty - two advanced stage non - small cell lung cancer patients were finally confirmed by pathohistological or cytological examination. All patients, after starting gamma knife radiosurgery, took orally targeted drugs erlotinib from August 2008 to August 2012,100 - 150 mg/d, 1 hour before meal eating or 2 hours after meal, uninterrupted medication for at least 2 months. The efficacy and toxic reactions were evaluated after at least one month at the end of gamma knife radiosurgery. Results In 42 patients, the objective response rate reached 19.0% （8/42） , the disease control rate reached 61.9% （26/42） , and the median time to disease progression was 5.2 months, the median survival time was 11.5 months. Major adverse effects were myelosuppression, lassitude and gastrointestinal tract reactions, most of which were Ⅰ/Ⅱ degree with less being Ⅲ/Ⅳ degree. Conclusions The efficacy of γ - SBRT in combined with targeted drug erlotinib on advanced stage non - small cell lung cancer is acceptable and adverse effects are tolerable.
出处
《武警医学》
CAS
2013年第7期608-610,共3页
Medical Journal of the Chinese People's Armed Police Force
关键词
非小细胞肺癌
立体定向放射治疗
靶向治疗
厄洛替尼
non- small cell lung cancer
stereotactic radiation therapy
targeted therapy
erlotinib
